Efficacy of anakinra in a patient with refractory relapsing polychondritis

Wendling, Daniel; Govindaraju, Sophie; Prati, Clément; Toussirot, Éric; Bertolini, Ewa

doi:10.1016/j.jbspin.2008.02.011

Cited by 35 publications

(8 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Accordingly, IL-1 antagonism has proved to be an effective treatment for both conditions [72][73][74]. Other autoinflammatory disorders have been linked to dysregulated inflammasome activity on the basis of their favourable response to anti-IL-1 therapy; however, in most of these [190,191] Schnitzler's syndrome Unknown Chronic urticarial skin rash, recurrent fever, arthralgia, myalgia Anakinra [192] Sweet syndrome Unknown, neutrophildependent Fever, skin lesions (violet papules, plaques or nodules), pulmonary symptoms (dyspnoea, cough)…”

Section: Autoinflammatory Syndromesmentioning

confidence: 99%

The NLRP3 inflammasome in health and disease: the good, the bad and the ugly

Vince

2011

Clinical and Experimental Immunology

344

313

View full text Add to dashboard Cite

While interleukin (IL)-1β plays an important role in combating the invading pathogen as part of the innate immune response, its dysregulation is responsible for a number of autoinflammatory disorders. Large IL-1β activating platforms, known as inflammasomes, can assemble in response to the detection of endogenous host and pathogen-associated danger molecules. Formation of these protein complexes results in the autocatalysis and activation of caspase-1, which processes precursor IL-1β into its secreted biologically active form. Inflammasome and IL-1β activity is required to efficiently control viral, bacterial and fungal pathogen infections. Conversely, excess IL-1β activity contributes to human disease, and its inhibition has proved therapeutically beneficial in the treatment of a spectrum of serious, yet relatively rare, heritable inflammasomopathies. Recently, inflammasome function has been implicated in more common human conditions, such as gout, type II diabetes and cancer. This raises the possibility that anti-IL-1 therapeutics may have broader applications than anticipated previously, and may be utilized across diverse disease states that are linked insidiously through unwanted or heightened inflammasome activity.

show abstract

Section: Autoinflammatory Syndromesmentioning

confidence: 99%

The NLRP3 inflammasome in health and disease: the good, the bad and the ugly

Vince

2011

Clinical and Experimental Immunology

344

313

View full text Add to dashboard Cite

show abstract

“…29,40,48 As for the other biological therapies, the IL-1 receptor antagonist, anakinra (100 mg/day), has been used after a lack of efficacy of anti-TNF agents, and the clinical spectrum is similar to them. 49,50 Abatacept (750 mg/mo) has limited reports and is used when 3 anti-TNF agents plus anakinra have failed. 51 TCZ (8 mg/kg/mo), an anti-IL-6 receptor blocker, is perhaps the most effective biological therapy for all, but its efficacy in airway involvement is the same as anti-TNF agents.…”

Section: Etiology and Pathophysiologymentioning

confidence: 99%

Relapsing polychondritis, an underestimated dermatological urgency: case report and literature review

et al. 2017

View full text Add to dashboard Cite

show abstract

“…After failure of prednisone, dapsone, several disease-modifying antirheumatic drugs, infliximab, and etanercept, she was successfully treated with anakinra (100 mg/day) beginning in 2007 2 Because she did not want to return to daily injections, monthly infusions of TCZ (8 mg/kg) were initiated. A clinical improvement was observed during the first week after the first infusion, but did not last, and no effect was seen after the second, despite normalization of CRP.…”

Section: Treatment Of Relapsing Polychondritis With Tocilizumabmentioning

confidence: 99%